(S)-2-(2-bromoacetyl)pyrrolidine-1-carboxylic acid tert-butyl ester | 152665-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-2-(2-bromoacetyl)pyrrolidine-1-carboxylic acid tert-butyl ester
• 英文别名: (S)-N-tert-butoxycarbonyl-2-bromoacetylpyrrolidine；N-Boc-(S)-2-bromoacetylpyrrolidine；(s)-Tert-butyl 2-(2-bromoacetyl)pyrrolidine-1-carboxylate；tert-butyl (2S)-2-(2-bromoacetyl)pyrrolidine-1-carboxylate
• CAS: 152665-75-3
• 化学式: C₁₁H₁₈BrNO₃
• 分子量: 292.173
• InChiKey: AHDOQGYAXYGUQV-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-(2-bromoacetyl)pyrrolidine-1-carboxylic acid tert-butyl ester 在 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 丙酮 为溶剂， 20.0 ℃ 、506.66 kPa 条件下， 反应 29.0h， 生成 (2R,2'S)-2-(2'-pyrrolidinyl)-7-hydroxy-1,4-benzodioxane
  参考文献：
  名称：

  Unichiral 2-(2′-Pyrrolidinyl)-1,4-benzodioxanes: the 2R,2′S Diastereomer of the N-Methyl-7-hydroxy Analogue Is a Potent α4β2- and α6β2-Nicotinic Acetylcholine Receptor Partial Agonist

  摘要：

  A series of unichiral 7-substituted 2-(1'-methyl-2'pyrrolidinyl)-1,4-benzodioxanes were synthesized and tested for the affinity for the alpha 4 beta 2 and alpha 7 central nicotinic receptors; the 2R,2'S diastereomer of the 7-OH analogue [(R,S)-7], unique in the series, has a high alpha 4 beta 2 affinity (12nM K-i). N-Demethylation and configuration inversion of the stereocenters greatly weaken its alpha 4 beta 2 affinity, confirming that such a rigid molecule can be considered a new template for alpha 4 beta 2 ligands. Docking analysis showed how (R,S)-7 is capable of strongly and specifically interacting with the amino acidic counterpart of the alpha 4 beta 2 receptor binding site. Further pharmacological characterization demonstrated that (R,S)-7 also has a high affinity for the alpha 6 beta 2 receptor, and in vitro functional tests indicated that it is a potent alpha 4 beta 2 and alpha 6 beta 2 partial agonist, with modest affinity and potency for the alpha 3 beta 4 receptor. Comparison with varenicline, a well-known nicotinic partial agonist used as a smoking cessation aid, interestingly reveals similar nicotinoid profiles.

  DOI：

  10.1021/jm200937t
• 作为产物：
  描述：

  tert-butyl (S)-2-(diazoacetyl)pyrrolidine-1-carboxylate 在 氢溴酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.08h， 生成 (S)-2-(2-bromoacetyl)pyrrolidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  CuI-Promoted One-Pot Synthesis of N-Boc Protected β-Ketotriazole Amino Acids: Application in the Synthesis of New Class of Dipeptidomimetics

  摘要：

  Nα-Boc-溴甲基酮、NaN3和丙炔酸的一锅点击化学反应以良好至优异的产率提供了N-Boc保护的1,4-二取代1,2,3-β-酮三唑酸。使用CuI作为催化剂和DMSO作为溶剂使得点击反应变得高效、实用且无需柱层析即可制备标题化合物。还阐述了所得非天然氨基酸作为构建模块制备含三唑的类肽的实用性。

  DOI：

  10.2174/092986612799363172

文献信息

• Peptidomimetics Through Click Chemistry: Synthesis of Novel β-Keto Triazole Acids from N-Protected Amino Acids
  作者：N. Narendra、T. M. Vishwanatha、Vommina V. Sureshbabu

  DOI：10.1007/s10989-010-9214-z

  日期：2010.12

  An efficient procedure for the preparation of azidomethylketones from N-urethane protected amino acids and their application in Cu(I) catalyzed azide-alkyne cycloaddition reaction are described. The synthesis has been carried out under mild conditions with all the commonly used urethane protected (Fmoc, Boc and Z) amino acids and the desired azides/triazoles were obtained in good yields. Incorporation of these triazole amino acids into small peptides generating dipeptidomimetics containing β-keto triazole units has also been demonstrated.

  描述了一种有效的程序，用于从N-氨基甲酸酯保护的氨基酸制备叠氮甲基酮及其在铜(I)催化的叠氮-炔烃环加成反应中的应用。该合成在温和条件下进行，适用于所有常用的氨基甲酸酯保护的氨基酸（Fmoc、Boc 和 Z），并以良好的产率获得了所需的叠氮化物/三唑化物。还展示了将这些三唑氨基酸纳入小肽中，生成含有β-酮三唑单元的二肽模仿物。
• [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014057435A1

  公开（公告）日：2014-04-17

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物，其中R和环A1、A2和A3如描述中所述，以及其药用盐，其制备方法，含有一个或多个公式(I)化合物的药物组合物，以及它们作为药物的用途，特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
• From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs
  作者：Christine Brotschi、Martin H. Bolli、John Gatfield、Bibia Heidmann、Francois Jenck、Catherine Roch、Thierry Sifferlen、Alexander Treiber、Jodi T. Williams、Christoph Boss

  DOI：10.1002/cmdc.201900618

  日期：2020.3.5

  The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone

  食欲素系统负责调节睡眠-觉醒周期。FDA批准Suvorexant是一种双orexin受体拮抗剂（DORA），用于治疗失眠症。在这里，我们报告了针对DORA的优化工作，我们的出发点是（5-甲氧基-4-甲基-2- [1,2,3]三唑-2-基-苯基）-（S）-2- [5-（2-三氟甲氧基-苯基）-[1,2,4]恶二唑-3-基]-吡咯烷-1-基}甲酮（6），是从我们内部研究计划中获得的化合物。化合物6被证明是一种有效的，可穿透大脑的DORA，在大鼠中的体内功效类似于suvorexant。然而，已发现低代谢稳定性，高血浆蛋白结合（PPB），低脑自由分数（fu brain）和低水溶性的缺点，因此化合物6不是进一步开发的理想候选者。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。
• Arphamenine and its related compounds, a process for their preparation and their use as medicaments
  申请人：MICROBIAL CHEMISTRY RESEARCH FOUNDATION

  公开号：EP0129163A1

  公开（公告）日：1984-12-27

  The present invention relates to Arphamenine-related compounds of the formula wherein R respresents an α-amino acid residue corresponding to an α-amino acid molecule from which the a-carboxyl group has been removed, to a process for their preparation, and their use as medicaments having immunopotentiating activity.

  本发明涉及如下式的阿法米宁相关化合物 其中 R 代表与去除了 a-羧基的 α-氨基酸分子相对应的α-氨基酸残基，本发明涉及其制备方法，以及其作为具有免疫增强活性的药物的用途。